Is exenatide the same as GLP-1?

No. It shares about 53% sequence identity with human GLP-1 and activates the same receptor, but it is a distinct peptide from a lizard.

Why is exenatide not degraded by DPP-4?

It carries glycine at the second position where human GLP-1 has alanine. DPP-4 recognises alanine or proline there and cannot process glycine.

Is exenatide still used?

It remains available but has been overtaken by longer-acting and more effective analogues. Its significance now is largely historical and mechanistic.

GLP-1 & Incretin Science

What Is Exenatide? From Gila Monster Venom to Medicine

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-233 cited sources

Exenatide is a synthetic form of exendin-4, a peptide isolated from the venom of the Gila monster, Heloderma suspectum. It was the first GLP-1 receptor agonist brought to market. Its natural resistance to DPP-4 comes from a glycine at the position where human GLP-1 carries alanine.

Key facts

Natural source: Heloderma suspectum venom (exendin-4)
Class: GLP-1 receptor agonist
Molecular weight: ~4,187 Da
Molecular formula: C184H282N50O60S
PubChem CID: 45588096
Homology to human GLP-1: About 53%
DPP-4 resistance: Natural — Gly at position 2
Significance: First GLP-1 agonist to reach market

Where it came from

Exendin-4 was isolated from the venom of the Gila monster, a venomous lizard native to the southwestern United States and Mexico. The peptide shares roughly 53% sequence identity with human GLP-1 — enough to activate the same receptor, far from identical. It is a genuine case of a therapeutic emerging from venom pharmacology rather than from rational design.

Why the lizard peptide solved the problem human GLP-1 could not

This is the elegant part. DPP-4 cleaves substrates carrying alanine or proline at the second position, and human GLP-1 has alanine there — which is why its half-life is one to two minutes. Exendin-4 has glycine at the equivalent position. DPP-4 does not process it. The resistance that semaglutide achieves through a synthetic Aib substitution, exendin-4 simply has by nature.

What that meant historically

It made a GLP-1 receptor agonist possible before anyone had engineered one. Every subsequent analogue is, in effect, an attempt to reproduce and improve on what exendin-4 already possessed — protease resistance first, then extended half-life through albumin binding. Exenatide established that sustained GLP-1 receptor agonism was clinically achievable.

Its limitations

Exenatide's half-life, while far longer than native GLP-1, is short by modern standards, and its effect size is modest against the compounds that followed. It is not a weight-management drug in the sense that semaglutide or tirzepatide are. Its importance is historical and mechanistic rather than competitive.

Why the origin story is worth knowing

It illustrates something about the field's structure. Venom peptides are evolutionarily optimised for potency and stability, because a venom component that degrades before reaching its target is useless to the animal. That makes venoms a productive source of protease-resistant peptide scaffolds, and exendin-4 is the most commercially significant example.

Extended research context

The GLP-1 & Incretin Science deep dive

Deep dive: the two routes to a bigger effect

Every compound trying to beat GLP-1 alone has taken one of two routes. The first adds more receptors from the same hormone family — GIP in tirzepatide, GIP and glucagon in retatrutide. The second adds a non-incretin satiety hormone, which in practice means amylin: CagriSema combines cagrilintide with semaglutide, and amycretin engages both receptors from one molecule. Both routes work, because they recruit signalling pathways that do not fully overlap. Neither has escaped the constraint that binds all of them, which is that gastrointestinal tolerability worsens as effect size grows.

Deep dive: why a percentage is not a result

The most-quoted numbers in this field are the least comparable. REDEFINE 1 reported 22.7% and 20.4% for the same compound in the same trial — the first among participants who adhered to treatment, the second across everyone randomised. TRIUMPH-1 reported 28.3% in an uncomplicated obesity population while TRIUMPH-3 reported up to 22.6% in adults with established cardiovascular disease, using the same compound. Before any two figures can be compared they have to match on estimand, population, duration, comparator and whether the number is placebo-adjusted. Most published comparisons match on none of them.

Deep dive: what happens after the trial stops

Every headline figure describes weight while treatment continues. The STEP-1 extension found that a year after semaglutide was stopped, participants had given back roughly two-thirds of what they lost, moving from 17.3% mean reduction to a net 5.6% — though average weight remained below baseline and nearly half stayed at least 5% down. Meta-analysis puts regain at around 0.8 kg per month. This is why maintenance studies such as TRIUMPH-6 matter more to the field's future than another two points of peak reduction.

Research applications

▸Comparing incretin and amylin compounds on a like-for-like basis
▸Interpreting estimands, thresholds and placebo-adjusted figures in trial reports
▸Tracking the obesity pipeline across sponsors and jurisdictions
▸Understanding receptor pharmacology behind GLP-1, GIP, glucagon and amylin
▸Distinguishing licensed medicines from investigational compounds

Handling checklist

✓Identify which estimand a quoted percentage comes from before citing it
✓Check the trial population and baseline BMI against the comparison you are making
✓Confirm the duration and whether the reduction curve had plateaued
✓Read discontinuation rates alongside efficacy figures
✓Verify every NCT identifier against ClinicalTrials.gov rather than secondary reporting

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Comparing headline percentages across different trials

Fix: Population, duration, estimand and comparator all differ; the numbers are not interchangeable.

✗ Quoting the larger of two figures from the same trial

Fix: Name the estimand. Efficacy and treatment-policy answer different questions.

✗ Treating peak reduction as a durable outcome

Fix: Substantial regain follows cessation across the class; peak figures describe a maintained state.

✗ Assuming an oral route means a weaker mechanism

Fix: Route and receptor count are independent. Orforglipron is weaker because it hits one receptor, not because it is a tablet.

✗ Reading investigational compounds as available treatments

Fix: Most of this pipeline holds no authorisation anywhere; mazdutide is approved only in China.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

Is exenatide the same as GLP-1?: No. It shares about 53% sequence identity with human GLP-1 and activates the same receptor, but it is a distinct peptide from a lizard.
Why is exenatide not degraded by DPP-4?: It carries glycine at the second position where human GLP-1 has alanine. DPP-4 recognises alanine or proline there and cannot process glycine.
Is exenatide still used?: It remains available but has been overtaken by longer-acting and more effective analogues. Its significance now is largely historical and mechanistic.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

More GLP-1 & Incretin Science articles

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum